Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

Michallet, MauricetteMauricetteMichalletDreger, PeterPeterDregerSobh, MohamadMohamadSobhKoster, LindaLindaKosterHoek, JenniferJenniferHoekBoumendil, ArianeArianeBoumendilScheid, ChristofChristofScheidFox, Christopher P.Christopher P.FoxWulf, GeraldGeraldWulfKrüger, WilliamWilliamKrügervan Gelder, MichelMichelvan GelderCorradini, PaoloPaoloCorradiniRusso, DomenicoDomenicoRussoPassweg, JakobJakobPasswegSchoemans, HélèneHélèneSchoemansBethge, WolfgangWolfgangBethgeSchaap, NicolaasNicolaasSchaapCornelissen, JanJanCornelissenBrowne, PaulPaulBrowneDurakovic, NadiraNadiraDurakovicMuller, LutzLutzMullerMontoto, SilviaSilviaMontotoKroger, NicolausNicolausKrogerSchetelig, JohannesJohannesSchetelig2021-04-142021-04-142019https://resolver.sub.uni-goettingen.de/purl?gro-2/82074enIbrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemiajournal_article10.1038/s41409-019-0742-7